Title:
PREDICTIVE METHODS BASED ON ALPHA-1-ACID GLYCOPROTEIN LEVELS
Document Type and Number:
WIPO Patent Application WO2000039590
Kind Code:
A3
Abstract:
A method for determining the dosage of a taxoid to administer to a patient who is being treated for cancer and whose body fluids include alpha-1-acid glycoprotein comprising observing the patient's level of alpha-1-acid glycoprotein, evaluating said level to determine the dosage of the taxoid to administer to the patient by comparing said level to a predetermined alpha-1-acid glycoprotein level derived from a population of patients having said cancer and treated with said taxoid at a common dosage and based on said evaluation, recommending the dosage of the taxoid to administer to the patient. Also, a method for assessing the effect of treatment of a patient who has cancer and who is being treated with a taxoid comprising observing the patient's alpha-1-acid glycoprotein level, comparing said level to a predetermined alpha-1-acid glycoprotein level derived from a population of patients having said cancer and treated with said taxoid at a common dosage and based on said comparison, assessing the effect of continued treatment of the patient with respect to the patient's response to treatment, the length of survival of the patient, or side effects that may be experienced by the patient. Also, a method for reducing the side effects experienced by a patient who has cancer and who is to be treated with a taxoid comprising observing the patient's alpha-1-acid glycoprotein (AAG) level, comparing said level to a predetermined alpha-1-acid glycoprotein level derived from a population of patients having said cancer and treated with said taxoid at a common dosage and based on said comparison recommending the dosage of said taxoid to administer to said patient to reduce the incidence or severity of side effects that the patient may experience during treatment with said taxoid.
More Like This:
Inventors:
BRUNO RENE (FR)
Application Number:
PCT/US1999/031284
Publication Date:
September 21, 2000
Filing Date:
December 30, 1999
Export Citation:
Assignee:
AVENTIS PHARM PROD INC (US)
BRUNO RENE (FR)
BRUNO RENE (FR)
International Classes:
G01N33/574; G01N33/68; (IPC1-7): G01N33/68
Other References:
VEYRAT-FOLLET C. ET AL.: "Application of clinical trial simulation in exploring the safety profile of docetaxel (D) in cancer patients", CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 65, no. 2, February 1999 (1999-02-01), pages 198, XP000908903
URIEN S. ET AL.: "Docetaxel serum protein binding with high affinity to alpha1-acid glycoprotein", INVESTIGATIONAL NEW DRUGS, vol. 14, 1996, pages 147 - 151, XP000908900
BRUNO R. ET AL.: "A population pharmacokinetic model for docetaxel (Taxotere): model building and correlation", JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, vol. 24, no. 2, - 1996, pages 153 - 172, XP000908881
BRUNO R. ET AL.: "Population pharmacokintetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer", J. CLIN. ONCOL., vol. 16, no. 1, January 1998 (1998-01-01), pages 187 - 196, XP000910385
GANZ P.A. ET AL.: "Monitoring the therapy of lung cancer with alpha-1-acid glycoprotein", CANCER RESEARCH, vol. 44, 1984, pages 5415 - 5421, XP000909045
GANZ P.A. ET AL.: "Evaluation of a radioimmunoassay for alpha-1-acid glycoprotein to monitor therapy of cancer patients", JOURNAL NATIONAL CANCER INSTITUTE (JNCI), vol. 71, no. 1, 1983, pages 25 - 30, XP000909046
BIENVENU J. ET AL.: "Laser nephelometry of orosomucoid in serum of newborns: reference intervals and relation to bacterial infections", CLIN. CHEM., vol. 27, no. 5, 1981, pages 721 - 726, XP002139731
KREMMER T. ET AL.: "Determination and analysis of human serum alpha-1-acid glycoprotein by liquid chromatographic methods", J. LIQUID CHROMATOGRAPHY, vol. 18, no. 6, 1995, pages 1207 - 1218, XP000909051
URIEN S. ET AL.: "Docetaxel serum protein binding with high affinity to alpha1-acid glycoprotein", INVESTIGATIONAL NEW DRUGS, vol. 14, 1996, pages 147 - 151, XP000908900
BRUNO R. ET AL.: "A population pharmacokinetic model for docetaxel (Taxotere): model building and correlation", JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, vol. 24, no. 2, - 1996, pages 153 - 172, XP000908881
BRUNO R. ET AL.: "Population pharmacokintetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer", J. CLIN. ONCOL., vol. 16, no. 1, January 1998 (1998-01-01), pages 187 - 196, XP000910385
GANZ P.A. ET AL.: "Monitoring the therapy of lung cancer with alpha-1-acid glycoprotein", CANCER RESEARCH, vol. 44, 1984, pages 5415 - 5421, XP000909045
GANZ P.A. ET AL.: "Evaluation of a radioimmunoassay for alpha-1-acid glycoprotein to monitor therapy of cancer patients", JOURNAL NATIONAL CANCER INSTITUTE (JNCI), vol. 71, no. 1, 1983, pages 25 - 30, XP000909046
BIENVENU J. ET AL.: "Laser nephelometry of orosomucoid in serum of newborns: reference intervals and relation to bacterial infections", CLIN. CHEM., vol. 27, no. 5, 1981, pages 721 - 726, XP002139731
KREMMER T. ET AL.: "Determination and analysis of human serum alpha-1-acid glycoprotein by liquid chromatographic methods", J. LIQUID CHROMATOGRAPHY, vol. 18, no. 6, 1995, pages 1207 - 1218, XP000909051
Download PDF:
Previous Patent: DETECTION OF PREACTIVATED PHAGOCYTES
Next Patent: COMPUTER NETWORK PHYSICAL-LAYER ANALYSIS METHOD AND SYSTEM
Next Patent: COMPUTER NETWORK PHYSICAL-LAYER ANALYSIS METHOD AND SYSTEM